In MDS, an initial study observed a significant correlation between the increased number of CD4+ Tregs in the blood and MDS subgroups according to the percentage of blast cells, the IPSS and the disease progression, making the quantification of CD4+ Tregs a potential biomarker of high-risk MDS [117]. The gene discussed is CD4; the disease is myelodysplastic syndrome.